All In Biotech

Drug Trial Radar · NCT05466643

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of DWP16001 as add-on Therapy to Drug A, With or Without Antihyperglycemic Drugs, in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

240

Planned (sponsor's estimate)

Start

Mar 17, 2023

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, placebo-controlled clinical trial, double-blind, parallel-group

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • DWP16001 0.3mgDrug

    1 tablet, Orally, Once daily single dose

  • DWP16001 PlaceboDrug

    1 tablet, Orally, Once daily single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from Baseline HbA1cTime frame: at Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.